157 related articles for article (PubMed ID: 30811063)
1. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F; Alix-Panabières C; Lafont T; Allal BC; Garrel R; Digue L; Guigay J; Cupissol D; Delord JP; Lallemant B; Alfonsi M; Aubry K; Mazel M; Becher F; Perriard F; Chatelut E; Thomas F
Br J Clin Pharmacol; 2019 Jun; 85(6):1357-1366. PubMed ID: 30811063
[TBL] [Abstract][Full Text] [Related]
2. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
3. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
6. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert TY; Kochanny S; Wood K; Worden FP; Adkins D; Wade JL; Sleckman BG; Anderson D; Brisson RJ; Karrison T; Stadler WM; Vokes EE
Cancer; 2020 Jul; 126(14):3237-3243. PubMed ID: 32365226
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS; Tatlı AM; Geredeli Ç; Atcı M; Besen AA; Mertsoylu H; Uysal M; Özdoğan M; Aydın SG; Bilici A; Karaağaç M; Artaç M; Kaplan MA; Ebinç S; Coşkun HŞ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):805-812. PubMed ID: 34312705
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Fukuda N; Yunokawa M; Fujiwara Y; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1322. PubMed ID: 33295110
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K; Gauler T; Dietz A; Grünwald V; Stöhlmacher J; Knipping S; Schroeder M; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U
Eur J Cancer; 2019 Nov; 122():53-60. PubMed ID: 31618704
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.
Garrel R; Mazel M; Perriard F; Vinches M; Cayrefourcq L; Guigay J; Digue L; Aubry K; Alfonsi M; Delord JP; Lallemant B; Even C; Daurès JP; Landais P; Cupissol D; Alix-Panabières C
Clin Chem; 2019 Oct; 65(10):1267-1275. PubMed ID: 31387885
[TBL] [Abstract][Full Text] [Related]
11. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
[TBL] [Abstract][Full Text] [Related]
12. Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Kim HR; Kang HN; Yun MR; Ju KY; Choi JW; Jung DM; Pyo KH; Hong MH; Ahn MJ; Sun JM; Kim HS; Kim J; Yoo J; Kim KR; Koh YW; Kim SH; Choi EC; Yoon SO; Shim HS; Paik S; Kim TM; Cho BC
Br J Cancer; 2020 Dec; 123(12):1720-1729. PubMed ID: 32963347
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
16. Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Bastit V; Bon-Mardion N; Picquenot JM; Rainville V; Moldovan C; François A; Loeb A; Thureau S; Manu D; Jardin F; Marie JP; Di Fiore F; Clatot F
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):541-550. PubMed ID: 30523411
[TBL] [Abstract][Full Text] [Related]
17. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
19. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
20. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
